OBJECTIVE: To review the published literature on prognostic factors in patients with node-negative breast cancer, focusing principally on recent studies with large sample sizes and extended follow-up periods. SUMMARY BACKGROUND DATA: Although numerous studies have examined prognostic factors in patients with breast cancer, relatively few have dealt specifically with node-negative disease, and interpretation has been limited by small sample size and limited follow-up times. METHODS: A review of the Medline database from 1996 to 2000 was undertaken, with additional papers published before 1996 identified through review articles. For inclusion in the analysis, papers needed to meet the following core criteria: 200 or more node-negative patients with invasive breast carcinoma; median follow-up time at least 5 years; method of testing and cut-off points specified; overall survival and/or disease-free survival specified; and relative risk or statistical probability values given for comparisons. RESULTS: Three or more papers that met the core criteria were retrieved for each of 11 potential prognostic factors. Of these, tumor size, tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic index, and vascular invasion showed a significant association with survival outcomes; HER2/neu and DNA ploidy showed no significant association; and estrogen receptor status and p53 showed mixed results. Lack of standardization in measurement techniques for many of the markers, including cathepsin-D, Ki-67, HER2/neu, and p53, limited their current clinical usefulness. CONCLUSIONS: In large studies with extended follow-up periods, tumor size, tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic index, and vascular invasion showed a significant association with survival outcome measures in patients with early-stage node-negative breast cancer. Because of technical difficulties and variations in the measurement of many of these factors, tumor size and tumor grade remain the only markers that currently have broad clinical usefulness for this patient group.
OBJECTIVE: To review the published literature on prognostic factors in patients with node-negative breast cancer, focusing principally on recent studies with large sample sizes and extended follow-up periods. SUMMARY BACKGROUND DATA: Although numerous studies have examined prognostic factors in patients with breast cancer, relatively few have dealt specifically with node-negative disease, and interpretation has been limited by small sample size and limited follow-up times. METHODS: A review of the Medline database from 1996 to 2000 was undertaken, with additional papers published before 1996 identified through review articles. For inclusion in the analysis, papers needed to meet the following core criteria: 200 or more node-negative patients with invasive breast carcinoma; median follow-up time at least 5 years; method of testing and cut-off points specified; overall survival and/or disease-free survival specified; and relative risk or statistical probability values given for comparisons. RESULTS: Three or more papers that met the core criteria were retrieved for each of 11 potential prognostic factors. Of these, tumor size, tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic index, and vascular invasion showed a significant association with survival outcomes; HER2/neu and DNA ploidy showed no significant association; and estrogen receptor status and p53 showed mixed results. Lack of standardization in measurement techniques for many of the markers, including cathepsin-D, Ki-67, HER2/neu, and p53, limited their current clinical usefulness. CONCLUSIONS: In large studies with extended follow-up periods, tumor size, tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic index, and vascular invasion showed a significant association with survival outcome measures in patients with early-stage node-negative breast cancer. Because of technical difficulties and variations in the measurement of many of these factors, tumor size and tumor grade remain the only markers that currently have broad clinical usefulness for this patient group.
Authors: P C Clahsen; C J van de Velde; C Duval; C Pallud; A M Mandard; A Delobelle-Deroide; L van den Broek; M J van de Vijver Journal: Eur J Surg Oncol Date: 1999-08 Impact factor: 4.424
Authors: P Rudolph; H Olsson; G Bonatz; V Ratjen; H Bolte; B Baldetorp; M Fernö; R Parwaresch; P Alm Journal: J Pathol Date: 1999-01 Impact factor: 7.996
Authors: N Quénel; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre Journal: Breast Cancer Res Treat Date: 1995-09 Impact factor: 4.872
Authors: G MacGrogan; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre Journal: Breast Cancer Res Treat Date: 1995 Impact factor: 4.872
Authors: J N Marcus; P Watson; D L Page; S A Narod; G M Lenoir; P Tonin; L Linder-Stephenson; G Salerno; T A Conway; H T Lynch Journal: Cancer Date: 1996-02-15 Impact factor: 6.860
Authors: P Broët; F Spyratos; S Romain; V Quillien; A Daver; G Ricolleau; A Rallet; C Toulas; B Asselain Journal: Br J Cancer Date: 1999-05 Impact factor: 7.640
Authors: Bryan J Dicken; Kathryn Graham; Stewart M Hamilton; Sam Andrews; Raymond Lai; Jennifer Listgarten; Gian S Jhangri; L Duncan Saunders; Sambasivarao Damaraju; Carol Cass Journal: Ann Surg Date: 2006-01 Impact factor: 12.969
Authors: Rafael Molina; Jose M Augé; Jose M Escudero; Xavier Filella; Gabriel Zanon; Jaume Pahisa; Blanca Farrus; Montserrat Muñoz; Martin Velasco Journal: Tumour Biol Date: 2010-04-02
Authors: Claire Verschraegen; Vincent Vinh-Hung; Gábor Cserni; Richard Gordon; Melanie E Royce; Georges Vlastos; Patricia Tai; Guy Storme Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: C A Purdie; L Baker; A Ashfield; S Chatterjee; L B Jordan; P Quinlan; D J A Adamson; J A Dewar; A M Thompson Journal: Br J Cancer Date: 2010-07-27 Impact factor: 7.640